Richard D. Francis - Feb 15, 2023 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
President and CEO
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis
Stock symbol
TEVA
Transactions as of
Feb 15, 2023
Transactions value $
$0
Form type
4
Date filed
2/17/2023, 06:03 AM
Previous filing
Jan 3, 2023
Next filing
Mar 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +485K $0.00 485K Feb 15, 2023 Ordinary Shares 485K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on February 15, 2023, with 161,655 vesting on each of February 15, 2024 and February 15, 2025, and 161,656 vesting on February 15, 2026.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.